NEW YORK, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against uniQure N.V. (NASDAQ: QURE) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired uniQure securities between September 24, 2025 and October 31, 2025, both dates ...

Core Viewpoint - A class action has been initiated for investors of UniQure N.V. who purchased securities during the specified class period, following a significant drop in stock price due to FDA feedback regarding their investigational gene therapy AMT-130 [1][3]. Group 1: Class Action Details - The Portnoy Law Firm is advising UniQure investors to file a lead plaintiff motion by April 13, 2026, if they bought securities between September 24, 2025, and October 31, 2025 [1]. - Investors can contact attorney Lesley F. Portnoy for legal rights discussions and to join the case [2]. Group 2: FDA Feedback and Stock Impact - On November 3, 2025, UniQure announced that the FDA no longer considers the data from Phase I/II studies of AMT-130 adequate for a Biologics License Application (BLA) submission, marking a significant shift from previous communications [3]. - Following this announcement, UniQure's stock price plummeted by $33.40 per share, or 49.34%, closing at $34.29 per share [3].

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 13, 2026 in uniQure Lawsuit - QURE [Accessibility Statement] Skip NavigationNEW YORK, Feb. 19, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of uniQure N.V. (NASDAQ: QURE).Shareholders who purchased shares of QURE during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recov ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against uniQure N.V. due to alleged violations of federal securities laws, encouraging affected investors to contact them for legal options [4][6]. Group 1: Allegations Against uniQure - The complaint alleges that uniQure and its executives made false and misleading statements regarding the FDA approval of the Pivotal Study design [6]. - It is claimed that the company downplayed the likelihood of needing to delay its Biologics License Application (BLA) timeline to conduct additional studies [6]. - The statements made by the defendants about the company's business and prospects are said to lack a reasonable basis [6]. Group 2: Impact of FDA Disclosure - On November 3, 2025, uniQure disclosed that the FDA no longer agreed that data from the Phase I/II AMT-130 studies would support a BLA submission, contradicting previous representations [7]. - Following this disclosure, uniQure's share price fell by $33.40, or over 49%, from $67.69 on October 31, 2025, to $34.29 on November 3, 2025 [8]. Group 3: Legal Proceedings - Investors who purchased uniQure securities between September 24, 2025, and October 31, 2025, are reminded of the April 13, 2026, deadline to seek the role of lead plaintiff in the class action lawsuit [4]. - The lead plaintiff is defined as the investor with the largest financial interest who directs the litigation on behalf of the class [9]. Group 4: Call for Information - Faruqi & Faruqi encourages anyone with information regarding uniQure's conduct, including whistleblowers and former employees, to contact the firm [10].

Core Viewpoint - A securities fraud class action lawsuit has been initiated against uniQure N.V., alleging misrepresentations related to its drug AMT-130, which is under development for Huntington's Disease treatment [5][6]. Group 1: Lawsuit Details - The lawsuit was filed in the United States District Court for the Southern District of New York on behalf of investors who purchased or acquired uniQure ordinary shares between September 24, 2025, and October 31, 2025 [5]. - The allegations include violations of the Securities Exchange Act of 1934 against uniQure and certain senior officers [5]. Group 2: Legal Actions and Deadlines - Investors wishing to serve as lead plaintiffs must file necessary documents by April 13, 2026 [4]. - Participation as a lead plaintiff is not required to share in any potential recovery from the lawsuit [4]. Group 3: Company Background - Bernstein Liebhard LLP, the law firm handling the case, has recovered over $3.5 billion for clients since its establishment in 1993 and has a strong track record in class action litigation [7].

Core Viewpoint - Kessler Topaz Meltzer & Check, LLP has filed a securities fraud class action lawsuit against uniQure N.V. on behalf of investors who purchased shares between September 24, 2025, and October 31, 2025, alleging material misstatements regarding the company's Huntington's disease gene therapy drug [1]. Group 1: Lawsuit Details - The lawsuit, titled Scocco v. uniQure N.V., was filed in the United States District Court for the Southern District of New York [1]. - The class period for the lawsuit is defined as September 24, 2025, to October 31, 2025, with a deadline for investors to seek lead plaintiff status by April 13, 2026 [1]. - The allegations include misleading statements about the Phase I/II clinical trials of uniQure's leading drug candidate, AMT-130, and the timeline for its Biologics License Application (BLA) submission to the FDA [1]. Group 2: Allegations Against uniQure - The complaint claims that uniQure misrepresented the approval status of the Pivotal Study design by the FDA and downplayed the likelihood of delays in the BLA timeline due to the need for additional studies [1]. - It is alleged that the defendants failed to disclose material adverse facts about uniQure's business and operations, leading to a lack of reasonable basis for their statements regarding the company's prospects [1]. Group 3: Investor Actions - Investors affected by the alleged fraud are encouraged to contact Kessler Topaz Meltzer & Check, LLP for a free case evaluation and to consider filing to be a lead plaintiff by the specified deadline [1]. - The lead plaintiff process allows investors to represent the class in directing the litigation, with the potential for recovery not affected by the decision to serve as lead plaintiff [1].

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of ordinary shares of uniQure N.V. during the specified Class Period, highlighting potential misrepresentations by the company regarding its drug candidate and regulatory approvals [1][5]. Group 1: Class Action Details - The class action lawsuit is for investors who purchased uniQure ordinary shares between September 24, 2025, and October 31, 2025 [1]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To participate in the class action, investors can submit their information through the provided link or contact the law firm directly [3][6]. Group 2: Allegations Against uniQure - The lawsuit claims that uniQure misrepresented the approval status of its Pivotal Study by the FDA and downplayed the likelihood of delays in its Biologics License Application (BLA) timeline [5]. - It is alleged that the company's statements regarding its business operations and prospects lacked a reasonable basis, leading to investor damages when the true information became public [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

Core Viewpoint - The Gross Law Firm is notifying shareholders of uniQure N.V. regarding a class action lawsuit due to alleged misleading statements and omissions related to the company's Pivotal Study and Biologics License Application timeline [1][3]. Group 1: Allegations - The complaint alleges that during the class period from September 24, 2025, to October 31, 2025, uniQure's management issued materially false and/or misleading statements [3]. - It is claimed that the design of uniQure's Pivotal Study was not fully approved by the FDA, which was not disclosed to investors [3]. - The likelihood of a delay in the Biologics License Application timeline due to the need for additional studies was downplayed, leading to a lack of reasonable basis in the company's statements about its business and prospects [3]. Group 2: Class Action Details - Shareholders are encouraged to register for the class action lawsuit by April 13, 2026, to potentially be appointed as lead plaintiffs [4]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case's progress [4]. - There is no cost or obligation for shareholders to participate in the case [4]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [5].

Company Overview - uniQure N.V. is a biotechnology company based in Amsterdam, specializing in gene therapies for rare and severe diseases. Its lead product candidate is AMT-130, which is currently in clinical trials for the treatment of Huntington's disease [2]. Legal Action - A class action lawsuit has been filed against uniQure on behalf of investors who acquired its securities between September 24, 2025, and October 31, 2025. The lawsuit alleges that the company misled investors regarding the design and progress of its pivotal study, leading to inflated market expectations for accelerated approval [1][3]. Stock Performance - Following the announcement of purported positive topline results on September 24, 2025, uniQure's shares surged nearly 250% in a single trading session. However, on November 3, 2025, the company disclosed that the FDA did not accept the Phase I/II study data as sufficient for a Biologics License Application (BLA) submission, resulting in a nearly 50% drop in share price, from $67.69 on October 31, 2025, to $34.29 on November 3, 2025 [3][4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against uniQure N.V. due to alleged violations of federal securities laws, particularly concerning misleading statements about the company's Pivotal Study and its implications for the BLA submission timeline [2][4]. Group 1: Allegations Against uniQure - The complaint alleges that uniQure and its executives made false and misleading statements regarding the FDA's approval of the Pivotal Study design [4]. - It is claimed that the company downplayed the likelihood of needing to delay its BLA submission due to additional studies required by the FDA [4]. - The statements made by the defendants about the company's business and prospects are said to lack a reasonable basis [4]. Group 2: Impact of Recent Disclosures - On November 3, 2025, uniQure disclosed that the FDA no longer agreed that data from the Phase I/II AMT-130 studies would support a BLA submission, leading to uncertainty about the submission timeline [5]. - Following this announcement, uniQure's share price fell by $33.40, a decline of over 49%, dropping from $67.69 on October 31, 2025, to $34.29 on November 3, 2025 [6]. Group 3: Legal Proceedings - Investors who purchased uniQure securities between September 24, 2025, and October 31, 2025, are encouraged to contact Faruqi & Faruqi to discuss their legal options, with a deadline of April 13, 2026, to seek the role of lead plaintiff in the class action [2][7]. - The lead plaintiff is defined as the investor with the largest financial interest in the relief sought by the class, who will oversee the litigation on behalf of the class members [7]. Group 4: Firm Background - Faruqi & Faruqi, LLP is a national securities law firm with a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [3].